Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD-Reference-Cited by-同舟云学术

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

Published:2019-01-22 Issue:2 Volume:3 Page:184-186
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Socié Gérard¹²³^ORCID,Milpied Noel⁴,Yakoub-Agha Ibrahim⁵,Bay Jacques-Olivier⁶,Fürst Sabine⁷,Bilger Karin⁸,Suarez Felipe⁹,Michallet Mauricette¹⁰,Lewalle Philippe¹¹,Liens David¹²,Mathis Catherine¹²,Guemas Eric¹³,Vernant Jean-Paul¹⁴

Affiliation:

1. Assistance Publique–Hôpitaux de Paris, Service d’Hématologie-Greffe, Hôpital Saint-Louis Lariboisière, Paris, France;

2. Université Paris 7 Denis Diderot, Paris, France;

3. INSERM Unite Mixte de Recherche 1160, Hôpital Saint-Louis Lariboisière, Paris, France;

4. Centre Hospitalier Universitaire (CHU) Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France;

5. CHU de Lille, Lille Inflammation Research International Center INSERM U995, Université Lille, Lille, France;

6. Service de Thérapie Cellulaire et Hématologie Clinique, CHU de Clermont-Ferrand, Clermont-Ferrand, France;

7. Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli Calmettes, Marseille, France;

8. Service d’Onco-Hématologie, CHU Hautepierre, Strasbourg, France;

9. Service d’Hématologie Adulte, Hôpital Necker, Paris, France;

10. Service d’Hématologie, Hôpital Lyon Sud, Pierre-Bénite, France;

11. Service d’Hématologie, Institut Jules Bordet, Brussels, Belgium;

12. Elsalys Biotech, Lyon, France;

13. Biossec, Paris, France; and

14. Service d’Hématologie Clinique, Hôpital Pitié Salpêtrière, Paris, France

Abstract

Abstract The treatment of steroid refractory acute graft-versus-host disease has been a significant clinical challenge. There have been relatively few randomized clinical trials comparing different treatment options. One such approach was the use of inolimomab (an anti-CD25 monoclonal antibody that blocks interleukin-2 signaling) that was compared to antithymocyte globulin in the INO107 phase 3 trial. Socié and colleagues report on the long-term follow-up of patients treated on this trial.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/2/184/1630737/advances028282.pdf

Reference5 articles.

1. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD;Socié;Blood,2017

2. How I treat refractory acute GVHD;Deeg;Blood,2007

3. Graft-versus-host disease;Ferrara;Lancet,2009

4. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation;Martin;Biol Blood Marrow Transplant,2012

5. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease;Macmillan;Blood,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second line extracorporeal photopheresis for cortico-resistant acute and chronic GVHD after allogeneic hematopoietic cell transplantation for hematological malignancies: Long-term results from a real-life study;Transfusion and Apheresis Science;2024-06

2. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation;Cell Transplantation;2024-01

3. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease;Expert Review of Clinical Immunology;2023-08-22

4. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials;Frontiers in Immunology;2023-06-20

5. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape;Leukemia;2022-09-24